treprostinil sodium · Liquidia Tech · NDA 213005
Yutrepia
Earliest generic entry, as listed · earliest of 4 marketed strengths
5 May 2037
Blocked by patent: US 10898494, US 11660304, US 11712442, US 11744835, US 11744836, US 12390475.
Listed patents · 6 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10898494 | use U-4200 | 5 May 2037 |
| US 11660304 | use U-4200 | 5 May 2037 |
| US 11712442 | use U-4200 | 5 May 2037 |
| US 11744835 | product | 5 May 2037 |
| US 11744836 | product | 5 May 2037 |
| US 12390475 | product | 5 May 2037 |
Exclusivities · 1 unexpired
| NP | new product | 23 May 2028 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 4
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 213005 · 001 · RLD | powder, inhalation | EQ 0.0265MG BASE/INH | 5 May 2037 |
| 213005 · 002 · RLD | powder, inhalation | EQ 0.053MG BASE/INH | 5 May 2037 |
| 213005 · 003 · RLD | powder, inhalation | EQ 0.0795MG BASE/INH | 5 May 2037 |
| 213005 · 004 · RLD | powder, inhalation | EQ 0.106MG BASE/INH | 5 May 2037 |